BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, April 5, 2026
Home » Blogs » BioWorld MedTech Perspectives » Med-tech tax repeal: Is tax reform a viable vehicle?

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Med-tech tax repeal: Is tax reform a viable vehicle?

March 4, 2013
By Mark McCarty
IRS_Building_Constitution_Avenue
Uncle Sam's vault. Will it ever be big enough?

Those who are following the medical device tax repeal story might also be buried in the weeds of the budget sequester, the continuing resolution and so on, and not without reason. After all, the resolution of these issues has a lot to do with how Medicare spending unfolds over the next seven months and beyond.

Much of the current hope for a repeal of the device tax seems to revolve around tax reform, so the question at this point is what will the tax reform discussion look like and whether it is viable as a vehicle for the device tax repeal. At the risk of seeming habitually pessimistic about the device tax repeal, the problem with the tax code overhaul as a vehicle for the repeal is that the two sides in this debate are approaching tax reform from what appears to be diametrically opposing points of view.

The Obama administration has made it clear since before the election of 2012 that an increase in tax revenues is its preferred means for dealing with the deficit. Reduced spending has not been the approach taken by President Obama, who has indicated that he will not settle for just an increase in rates, that he also wants to close out some tax loopholes as well.

Tax reform as House Republicans will propose it will likely consist of some closure of loopholes along with some lowering of rates, a sharp contrast to the President’s approach, which will be to attempt to bolster government revenues by leaving rates where they are – after all, he got what he wanted in terms of rates in the tax fight ending in January – and by closing loopholes.

Those who see room for compromise might cite Sen. Kelly Ayotte (R-New Hampshire), who indicated in a March 3 interview on This Week that she and Senate Republicans might be on board with tax reform that boosts revenues for Uncle Sam, but that’s not where House Speaker John Boehner is.

Boehner is in the driver’s seat where a Republican tax reform proposal is concerned, and it’s not that it doesn’t matter what Ayotte thinks. It’s just that it matters much more what Boehner thinks. Boehner said on Meet the Press, “the President got his tax hikes,” adding “the issue here is spending.”

There is little reason to think tax reform will be taken up in a serious fashion before the congressional recess in August simply because as soon as Congress gets past the continuing resolution/budget sequester issue, the matter of fiscal 2014 spending will surface. There are a scant seven months to come to terms with FY 2014, which means most if not all other issues of a fiscal nature will receive very little attention in the meantime.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • Illustration of a nerve cell with DNA double helix

    Molecular signatures show subtypes in neurodegenerative diseases

    BioWorld Science
    Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing